May 10, 2022
|
UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates
|
May 5, 2022
|
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
|
April 21, 2022
|
UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting
|
April 19, 2022
|
UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration
|
April 12, 2022
|
UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema
|
March 15, 2022
|
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
|
March 1, 2022
|
UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
|
February 14, 2022
|
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
|
February 3, 2022
|
UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
|
February 2, 2022
|
UNITY Biotechnology Reports Granting of New Employment Inducement Award
|